Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Protalix Biotherapeutics
(NY:
PLX
)
0.9163
-0.0037 (-0.40%)
Streaming Delayed Price
Updated: 12:49 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Protalix Biotherapeutics
< Previous
1
2
3
Next >
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024
August 14, 2024
PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 17, 2024
Via
Benzinga
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024
May 10, 2024
PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 10, 2024
Via
Benzinga
Pullix Gains Momentum As Gamestop Exits NFT Space
January 14, 2024
Notable NFT news this week is from video game retailer GameStop, which has announced its NFT marketplace will shut down next month. The publicly-traded company is citing “regulatory uncertainty” for...
Via
Talk Markets
Earnings Scheduled For November 6, 2023
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
Earnings Preview For Protalix BioTherapeutics
November 03, 2023
Via
Benzinga
Preview: Protalix BioTherapeutics's Earnings
August 04, 2023
Via
Benzinga
Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil
May 04, 2023
Via
Benzinga
Earnings Scheduled For March 14, 2024
March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
Via
Benzinga
Earnings Preview: Protalix BioTherapeutics
March 13, 2024
Via
Benzinga
Earnings Preview For Protalix BioTherapeutics
February 24, 2023
Via
Benzinga
Looking Into Protalix BioTherapeutics's Return On Capital Employed
December 23, 2022
Via
Benzinga
Protalix BioTherapeutics Well Placed to Advance in 2023
December 12, 2022
We see a number of reasons to be positive about PLX shares in 2023 and investors should take note.
Via
Talk Markets
Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying
October 23, 2023
The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 07, 2023
Via
Benzinga
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
May 10, 2023
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May 10, 2023
It's time for another dive into the biggest pre-market stock movers as we see what shares are on rising and falling on Tuesday!
Via
InvestorPlace
Earnings Scheduled For May 16, 2022
May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Via
Benzinga
Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket
February 27, 2023
Gainers Lucira Health, Inc. (NASDAQ: LHDX) rose 228.5% to $0.46 in pre-market trading after the FDA authorized Lucira's over-the-counter at-home test to detect both influenza and COVID-19 viruses.
Via
Benzinga
$12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying
January 06, 2023
The Dow Jones closed lower by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
November 30, 2022
By David Willey, Benzinga
Via
News Direct
Exposures
Product Safety
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
November 30, 2022
Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted a Biologics License...
Via
TheNewswire.com
Exposures
Product Safety
Earnings Scheduled For February 27, 2023
February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via
Benzinga
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
November 29, 2022
Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group,
Via
Benzinga
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
September 21, 2022
As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a...
Via
TheNewswire.com
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
September 21, 2022
By Mark Gilman, Benzinga
Via
News Direct
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
September 20, 2022
As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a...
Via
Benzinga
Earnings Scheduled For November 14, 2022
November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Via
Benzinga
Earnings Scheduled For August 15, 2022
August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.